Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its pipeline candidate, fosgonimeton for the treatment of mild-to-moderate Alzheimer's disease (AD). Shares of the company were up 29.4%, following the announcement of the news. The LIFT-AD study evaluates once-daily fosgonimeton (40 mg) subcutaneous injection versus placebo over a treatment period of 26 weeks in mild-to-moderate AD patients. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of AD. The primary endpoint of the LIFT-AD study is to see the change from baseline following 26 weeks of treatment using the Global Statistical Test, which evaluates cognition and function, the two key measures of disease progression. Other secondary and exploratory endpoints are changes in plasma biomarkers of neurodegeneration, protein pathology and neuroinflammation. Alzheimer's disease is a devastating neurodegenerative disorder characterized by the accumulation of tau tangles and amyloid beta (Aβ) plaques in the brain. Shares of Athira have rallied 39.5% in the year so far against the industry's decline ...